McKesson (NYSE:MCK) Releases FY21 Earnings Guidance

McKesson (NYSE:MCK) updated its FY21 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $13.95-14.75 for the period, compared to the Thomson Reuters consensus estimate of $15.48. The company issued revenue guidance of +2-4% to $218.6-222.9 billion, compared to the consensus revenue estimate of $234.49 billion.McKesson also updated its FY 2021
Pre-Market guidance to 13.95-14.75 EPS.

MCK stock opened at $149.42 on Friday. McKesson has a 52 week low of $112.60 and a 52 week high of $172.18. The company has a market capitalization of $25.80 billion, a PE ratio of 29.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.82. The company’s 50-day simple moving average is $136.14 and its 200 day simple moving average is $142.81. The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.56 and a current ratio of 0.99.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $4.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.10 by $0.17. McKesson had a net margin of 0.39% and a return on equity of 41.07%. The firm had revenue of $58.54 billion during the quarter, compared to the consensus estimate of $55.60 billion. During the same quarter in the previous year, the firm posted $3.69 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts forecast that McKesson will post 15.01 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date of this dividend is Friday, May 29th. McKesson’s dividend payout ratio is currently 10.97%.

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on McKesson from $186.00 to $187.00 and gave the company an overweight rating in a report on Wednesday, March 18th. TheStreet upgraded McKesson from a c rating to a b rating in a research report on Wednesday. Cowen upped their price objective on shares of McKesson from $174.00 to $186.00 and gave the stock an outperform rating in a research report on Thursday. Guggenheim raised shares of McKesson from a neutral rating to a buy rating in a report on Friday, March 13th. Finally, Goldman Sachs Group upgraded shares of McKesson from a neutral rating to a buy rating and boosted their target price for the company from $173.00 to $174.00 in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. McKesson currently has a consensus rating of Buy and an average target price of $168.50.

In related news, CEO Brian S. Tyler sold 4,063 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $135.00, for a total transaction of $548,505.00. Following the completion of the transaction, the chief executive officer now directly owns 16,255 shares in the company, valued at approximately $2,194,425. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 8,187 shares of company stock worth $1,064,057. 0.88% of the stock is currently owned by corporate insiders.

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Featured Story: What is a Buy-Side Analyst?

Earnings History and Estimates for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.